Therapeutic Solutions International (TSOI) 10-Q 26 Jul 16 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Jul. 20, 2016
Document and Entity Information:
Entity Registrant Name	THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Trading Symbol	tsoi
Amendment Flag	false
Entity Central Index Key	1,419,051
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		682,751,000
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 37,290	$ 2,894
Accounts Receivable	328	0
Inventories	28,519	0
Prepaid expenses and other current assets	66,092	139,016
Assets from discontinued operations	0	46,845
Total current assets	132,229	188,756
Other non-current assets	12,476	12,461
Property and equipment, net	0	0
Total assets	144,705	201,217
Current liabilities:
Accounts payable	270,583	290,554
Accrued expenses and other current liabilities	19,157	14,777
Due to related parties	26,473	27,174
Total current liabilities	316,214	332,505
Shareholders' Equity
Preferred stock, $.001 par value; 5,000,000 shares authorized	0	0
Common stock, $.001 par value; 699,999,999 shares authorized, 463,000,000 issued and outstanding at June 30, 2015 and 699,999,999 shares authorized, 400,000,000 issued and outstanding at December 31, 2014	463,000	400,000
Capital in excess of par	2,187,809	2,093,009
Deficit accumulated	(2,822,317)	(2,624,296)
Total shareholders' equity	(171,509)	(131,288)
Total liabilities and shareholders' equity	$ 144,705	$ 201,217

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets Parentheticals - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Parentheticals
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	5,000,000	5,000,000
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	699,999,999	699,999,999
Common Stock, shares issued	463,000,000	400,000,000
Common Stock, shares outstanding	463,000,000	400,000,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenue:
Net Sales	$ 420	$ 0	$ 420	$ 0
Cost of Goods Sold	97	0	97	0
Gross Profit	323	0	323	0
Operating expenses:
General and administrative	20,297	12,315	33,146	26,791
Salaries, wages, and related costs	73,723	74,790	122,166	101,418
Selling expenses	328	0	482	0
Amortization and depreciation	0	5,283	0	10,566
Consulting	27,500	2,567	28,333	33,870
Legal and professional	(8,262)	32,513	4,338	75,128
Total operating expenses	113,586	127,468	188,466	247,774
Loss from operations	113,263	127,468	188,143	247,774
Other income (expense):
Net other income/(expense)	1,480	4,171	1,682	(780)
Interest expense	(1,296)	(2,895)	(2,839)	(5,078)
Total other income (expense)	184	1,276	(1,157)	(5,858)
Net income (loss) from continuing operations	(113,078)	(126,192)	(189,622)	(253,631)
Net income from discontinued operations	(8,722)	65,219	(8,722)	148,570
Net income (loss)	$ (121,800)	$ (60,973)	$ (198,021)	$ (105,061)
Basic and diluted loss per common share
Continuing operation	$ 0	$ 0	$ 0	$ 0
Discontinued operation.	$ 0	$ 0	$ 0	$ 0
Weighted average shares outstanding	452,032,967	165,787,059	426,767,956	130,380,102

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Changes in Shareholders' (Deficit) - USD ($)	Common Stock	Common Stock Amount	Additional Paid-in Capital	Earnings (Deficit) Accumulated	Total
Balance at Dec. 31, 2013	94,466,400	94,466	1,665,725	(2,335,546)	(575,355)
Stock issued for service on March 31, 2014	12,000,000	12,000	33,750	0	45,750
Stock issued for note conversion on June 30, 2014	90,000,000	90,000	180,000	0	270,000
Stock issued for note conversion on September 30, 2014	103,533,600	103,534	103,534	0	207,067
Stock issued for a material definitive agreement	100,000,000	100,000	110,000	0	210,000
Net Loss, December 31, 2014		$ 0	$ 0	$ (288,750)	$ (288,750)
Balance at Dec. 31, 2014	400,000,000	400,000	2,093,009	(2,624,296)	(131,288)
Stock issued on March 27, 2015	20,000,000	20,000	30,000	0	50,000
Stock issued on April 17, 2015	20,000,000	20,000	30,000	0	50,000
Stock issued on June 8, 2015	1,000,000	1,000	1,500	0	2,500
Stock issued for services on February 27, 2015	2,000,000	2,000	3,000	0	5,000
Stock issued for services on April 1, 2015	10,000,000	10,000	15,000	0	25,000
Stock issued for services on June 1, 2015	7,000,000	7,000	10,500	0	17,500
Stock issued for services on June 1, 2015	3,000,000	3,000	4,800	0	7,800
Net Loss, June 30, 2015		$ 0	$ 0	$ (198,021)	$ (198,021)
Balance at Jun. 30, 2015	463,000,000	463,000	2,187,809	(2,822,317)	(171,509)

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities
Net loss	$ (198,021)	$ (105,061)
Non-cash expenses:
Depreciation	0	10,566
Stock based compensation to consultants	55,300	45,750
Stock based note conversion to officers	0	270,000
Changes in operating assets and liabilities:
(Increase) decrease in inventory	(28,519)	0
(Increase) decrease in accounts receivable	(328)	0
(Increase) decrease in prepaid expenses and other current assets	72,924	(29,804)
(Increase) decrease in other assets	(14)	(20)
Increase (decrease) in accounts payable	(19,971)	(10,255)
Increase (decrease) in accrued expenses and other current liabilities	4,381	(180,292)
Increase (decrease) in other related party liabilities	(701)	(2,521)
Cash used by operating activities-continuing operations	(114,949)	(1,637)
Cash provided (used) by operating activities-discontinued operations	46,845	(3,013)
Net cash used by operating activities	(68,104)	(4,648)
Cash flows from investing activities
Acquisition of fixed assets	0	0
Net cash used by investing activities	0	0
Cash flows from financing activities
Stock issuance	102,500	0
Repayments	0	(5,000)
Net cash provided by financing activities	102,500	(5,000)
Increase in cash	34,396	(9,650)
Cash at beginning of period	2,894	12,513
Cash at end of period	37,290	2,863
Supplemental Cash Flow Information:
Cash paid for interest	1,731	1,373
Cash paid for income taxes	$ 800	$ 800

Organization and Presentation B

Organization and Presentation Basis	6 Months Ended
	Jun. 30, 2015
Organization and Presentation Basis:
Organization and Presentation Basis	Note 1 – Organization and Presentation Basis The consolidated financial statements included herein have been prepared by Therapeutic Solutions International, Inc. (the “Company”), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). In the opinion of the management of the Company, these interim Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair presentation of the Company’s financial position as of June 30, 2015 and the results of operations for the three and six months ended June 30, 2015 and 2014. Interim results are not necessarily indicative of results for a full year or for any future period. The consolidated financial statements and notes included herein are presented as required by Form 10-Q, and do not contain certain information included in our audited financial statements and notes for the fiscal year ended December 31, 2014 pursuant to the rules and regulation of the SEC. For further information, refer to the financial statements and notes thereto as of and for the year ended December 31, 2014, and included in the Annual Report on Form 10-K on file with the SEC. Therapeutic Solutions International, Inc. (the “Company”) was organized August 6, 2007 under the name Friendly Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation organized September 21, 2010 (“Splint”). Splint is treated as the “accounting acquirer” in the accompanying financial statements. Until April 28, 2014 the Company sold (directly and through distributors and sublicensees), in non-US countries, plastic intraoral devices known as Anterior Midpoint Stop Appliances (“AMPSA Products”) . On April 28, 2014, we received a letter from Mr. J. Christopher Jaczko, a lawyer with the Procopio law firm in San Diego who represents Boyd Research, Inc. and related parties. In his letter, Mr. Jaczko notified us that our license to use the international patents for our AMPSA device, pursuant to our license agreement with his clients effective January 1, 2013, was terminated. The ostensible reason given was our failure to make certain unspecified payments due under the license agreement to his clients. We disputed the termination, but believed that the costs involved with litigating the termination of the New License was not in the best interest of the Company and its shareholders. Therefore, the Company moved in a new direction. Currently the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. Activating one’s immune system is now a well-accepted method to cure certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. On the other hand, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions. TSI is developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. The following outlines our relationships and divisions to focus on each of these programs: Nutraceutical Division – TSI has been producing high quality nutraceuticals. Its flagship product, ProJuvenol ® ® OmniBiome, Inc., (“OMNI”) - is a partially-subsidiary of TSI, incorporated in the State of Delaware on October 20, 2015, where the intellectual property surrounding probiotics is housed. On November 18, 2015 the Company licensed to OmniBiome, Inc. certain intellectually property. The License agreement in its entirety may be read as an exhibit filed with Form 8K: https://www.sec.gov/Archives/edgar/data/1419051/000107878215001890/f8k111715_ex10z1.htm Licensed Patent Rights: Shall mean: a. Patent Application Serial No. 62/213260 filed 9-02-2015 by Licensor. b. Patent Application Serial No. 62/219020 filed 9-15-2015 by Licensor. c. Patent Application Serial No. 62/232722 filed 9-25-2015 by Licensor. 1. Initial Payment and Royalty Rate. For the licensed herein granted: (a) Licensee agrees to pay a sign-up fee of $ 50,000.00. (b) Licensee shall pay on earned royalty of Five Percent (5 %) of Licensee’s Gross Sales of Products and fifty percent (50%) of the sublicensing receipts. (c) Licensee shall pay an annual minimum royalty fee of Fifteen Thousand Dollars ($15,000.00) for each licensed Product. On December 4, 2015 the Company licensed to OmniBiome, Inc. certain intellectually property. The License agreement in its entirety may be read as an exhibit filed with Form 8K: https://www.sec.gov/Archives/edgar/data/1419051/000107878215001971/f8k120815_ex10z2.htm Licensed Patent Rights: Shall mean: a. Patent Application Serial No. 62/194990 filed 7-21-2015 by Licensor. 1. Initial Payment and Royalty Rate. For the licensed herein granted: (a) Licensee agrees to pay a sign-up fee of $ 50,000.00. (b) Licensee shall pay on earned royalty of Five Percent (5 %) of Licensee’s Gross Sales of Products and fifty percent (50%) of the sublicensing receipts. (c) Licensee shall pay an annual minimum royalty fee of Fifteen Thousand Dollars ($15,000.00) for each licensed Product. Current programs focus on the use of probiotics to prevent pre-term labor and on using probiotics to reverse periodontal disease. The Officers and Directors of the Company are also officers and Directors of Omni. As of July 20, 2016 TSI owns approximately 73.75% of the outstanding shares of Omni. MolecuVax, Inc., (“MVAX”) – is a partially-owned subsidiary of TSI, incorporated in the State of Delaware on October 28, 2015, where the intellectual property surrounding immune-oncology is housed. On February 8, 2015 the Company licensed to MolecuVax, Inc. certain intellectually property. The License agreement in its entirety may be read as an exhibit filed with Form 8K: https://www.sec.gov/Archives/edgar/data/1419051/000107878216002281/f8k020816_ex10z1.htm Licensed Patent Rights: Shall mean: a. Patent Application Serial No. 62/258007 filed 11-20-2015 by Licensor. 1. Initial Payment and Royalty Rate. For the licensed herein granted: (a) Licensee agrees to pay a sign-up fee of $ 100,000.00. (b) Licensee shall pay on earned royalty of Five Percent (5 %) of Licensee’s Gross Sales of Products and fifty percent (50%) of the sublicensing receipts. (c) Licensee shall pay an annual minimum royalty fee of Thirty Thousand Dollars ($30,000.00) for each licensed Product. The programs within MolecuVax include using exosomes derived from various immune cells to attack cancers as well as developing a cancer vaccine against cancers that express a certain protein unique to them. The Officers and Directors of the Company are also officers and Directors of MVAX. As of July 20, 2016 TSI owns approximately 21.5% of the outstanding shares of MVAX. Website: www.molecuvax.com. Capo Therapeutics, Inc. Capo Therapeutics, Inc., (“CAPO”) – is a Delaware Corporation incorporated on March 28, 2016. The main focus of Capo Therapeutics is the development of an effective and safe vaccine against Alzheimer’s Disease (AD), one of the most devastating diseases of the century. Amyloid-beta (Ab) immunotherapy is considered to be a promising approach to reducing the level of Ab in the CNS of AD patients. However, data from the first clinical trial AN1792 indicated that vaccine should be designed not to induce autoreactive cellular responses and to be effective in the majority of the individuals from the risk groups. The Officers and Directors of the Company are also officers and Directors of CAPO. As of July 20, 2016 TSI owns approximately 6.5% of the outstanding shares of CAPO. Website: www.capotherapeutics.com.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Significant Accounting Policies:
Significant Accounting Policies	Note 2 – Significant Accounting Policies Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash For the Statements of Cash Flows, all highly liquid investments with maturity of three months or less are considered to be cash equivalents. There were no cash equivalents as of June 30, 2015 and 2014. Other assets include restricted cash of $10,000 that is used to secure a company credit card. Inventory Inventory consists of finished goods, and is stated at the lower of cost or market. The Company records cost of sales using the moving average cost method. There was no excess or obsolete inventory reserve at June 30, 2015 and December 31, 2014. Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutrasecutal formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. During the year ended December 31, 2014, the Company recognized an impairment charge of $210,000 for intangible assets. Income Taxes The Company accounts for income taxes under ASC 740 “Income Taxes,” “Accounting for Income Taxes” “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” Going Concern The Company’s financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has experienced recurring losses over the past years which have resulted in accumulated deficits of approximately $2,822 thousand and a working capital deficit of approximately $184 thousand at June 30, 2015. These conditions raise uncertainty about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is contingent upon its ability to secure additional financing, increase sales of its products and attain profitable operations. It is the intent of management to continue to raise additional capital. However, there can be no assurance that the Company will be able to secure such additional funds or obtain such on terms satisfactory to the Company, if at all. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Share Based Expenses ASC 718 “Compensation - Stock Compensation,” The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50 “Equity-Based Payments to Non-Employees,” “Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring or in Conjunction with Selling, Goods or Services”. Recently Implemented Standards The Company has implemented all new accounting pronouncements that are in effect that may impact its financial statements and does not believe that there are any new accounting pronouncements that have been issued that might have a material impact on its financial statements.

Restricted Cash

Restricted Cash	6 Months Ended
	Jun. 30, 2015
Restricted Cash:
Restricted Cash	Note 3 – Restricted Cash Other non-current asset is a $10,000 certificate of deposit with an annual interest rate of 0.6%. This certificate matures on June 17, 2017, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.

Equipment

Equipment	6 Months Ended
	Jun. 30, 2015
Equipment
Equipment	Note 4 – Equipment The cost and accumulated depreciation of fixed assets and equipment at June 30, 2015 and December 31, 2014 are summarized below: June 30, 2015 December 31, 2014 Computer Hardware $ 10,747 $ 10,747 Office Furniture and Equipment 3,639 3,639 Shipping and Other Equipment 1,575 1,575 Total 15,961 15,961 Accumulated Depreciation (15,961) (15,961) Property and Equipment, net $ - $ - Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Depreciation expenses for the six months ended June 30, 2015 and year ended December 31, 2014 were $0 and $21,133, respectively.

Intangible Asset

Intangible Asset	6 Months Ended
	Jun. 30, 2015
Intangible Asset:
Intangible Asset	Note 5 - Intangible Asset On December 9, 2014 the Company contractually obtained the rights, title and interest in and to proprietary formulations for two nutritional supplement products known under the trade names: (a) “T-Rx”; and, (b) “Vital Female; and, the purchase of all legal right, title and interest, in and to intellectual property including, but not limited to, Innovative’s nutritional supplement product known under the trade name: “Projuvenol.” The Company issued 100,000,000 shares for this rights, title and interest. The fair value of the 100,000,000 shares of common stock of $210,000 has been recorded as intangible assets. On December 31, 2014, the Company performed an impairment test on the intellectual property, and the Company recorded an impairment of $210,000.

Equity Transactions

Equity Transactions	6 Months Ended
	Jun. 30, 2015
Equity Transactions
Equity Transactions	Note 6 – Equity Transactions Preferred Stock The Company is authorized to issue 5,000,000 shares of $.001 par value preferred stock. The Company has not issued any preferred stock. Common Stock The Company is authorized to issue 699,999,999 shares of $.001 par value common stock. All shares have equal voting rights, are non-assessable, and have one vote per share. Voting rights are not cumulative and, therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all of the directors of the Company. On March 31, 2014, we issued 2,500,000 shares of common stock, valued at $.0035 per share, for consulting services. On March 31, 2014, we issued 2,500,000 shares of common stock, valued at $.004 per share, for consulting services. On March 31, 2014, we issued 2,000,000 shares of common stock, valued at $.0035 per share, for consulting services. On March 31, 2014, we issued 5,000,000 shares of common stock, valued at $.004 per share, for legal services. On June 19, 2014, we issued 45,000,000 shares of common stock, valued at $.003 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On June 19, 2014, we issued 45,000,000 shares of common stock, valued at $.003 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 26,562,500, shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 21,476,435shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 26,562,500 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 21,250,000 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 7,682,165 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On December 9, 2014, we issued 100,000,000 shares of common stock, valued at $.0021 per share, in regard to a Material Definitive Agreement (Form 8-K filed on December 10, 2014). On March 27, 2015, we issued 20,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On March 27, 2015, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On April 1, 2015, we issued 10,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On April 17, 2015, we issued 20,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On June 1, 2015, we issued 3,000,000 shares of common stock, valued at $.0026 per share, for consulting services. On June 1, 2015, we issued 7,000,000 shares of common stock, valued at $.0025 per share, for legal services On June 8, 2015, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On July 15, 2015, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On August 31, 2015, we issued 10,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On September 25, 2015, we issued 5,000,000 shares of common stock, valued at $.0046 per share, for consulting services. On October 1, 2015, we issued 23,000,000 shares of common stock, valued at $.0063 per share, for consulting services. On October 14, 2015, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On October 16, 2015, we issued 4,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 9, 2015, we issued 3,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 17, 2015, we issued 7,500,000 shares of common stock, valued at $.0041 per share, for consulting services. On November 23, 2015, we issued 20,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 30, 2015, we issued 2,500,000 shares of common stock, valued at $.01 per share, for legal services. On January 4, 2016, we issued 2,500,000 shares of common stock, valued at $.004 per share, for consulting services. On January 22, 2016, we issued 2,500,000 shares of common stock, valued at $.0035 per share, for consulting services. On February 1, 2016, we issued 2,500,000 shares of common stock, valued at $.003 per share, for consulting services. On February 5, 2016, we issued 8,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On February 22, 2016, we issued 5,451,000 shares of common stock, valued at $.003 per share, in regard to a License Agreement (Form 8-K filed on February 25, 2016). On February 26, 2016, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On March 7, 2016, we issued 10,000,000 shares of common stock, valued at $.004 per share, for consulting services. On March 21, 2016, we issued 100,800,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On May 2, 2016, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement and 1,000,000 shares of common stock, valued at $.0053 per share, for consulting services. On May 26, 2016, we issued 2,500,000 shares of common stock, valued at $.0066 per share, for consulting services. On May 26, 2016, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On May 31, 2016, we issued 2,500,000 shares of common stock, valued at $.0066 per share, for legal services.

Discontinued Operation

Discontinued Operation	6 Months Ended
	Jun. 30, 2015
Discontinued Operation:
Discontinued Operation	Note 7 – Discontinued Operation On April 28, 2014, we received a letter from Mr. J. Christopher Jaczko, a lawyer with the Procopio law firm in San Diego who represents Boyd Research, Inc. and related parties. In his letter, Mr. Jaczko notified us that our license to use the international patents for our AMPSA device, pursuant to our license agreement with his clients effective January 1, 2013, was terminated. The following are the summarized results of discontinued operations for the three and six months ended June 30, 2015 and 2014 and the Balance Sheet as of June 30, 2015and December 31, 2014: For the Three Months ended June 30, 2015 For the Three Months ended June 30, 2014 For the Six Months ended June 30, 2015 For the Six Months ended June 30, 2014 Net international revenues $ - $ 68,879 $ - $ 144,298 Cost of goods sold - (1,663) - (3,583) Selling expenses - (1,997) - (4,578) Bad debt (4,670) - (4,670) - Obsolete inventory (4,052) - (4,052) - Other income from discontinued operations - - - 12,433 $ (8,772) $ 65,219 $ (8,772) $ 148,570 June 30, 2015 December 31, 2014 Assets Accounts Receivable, net - 46,845 Total assets of discontinued operations $ - $ 46,845

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2015
Related Party Transactions:
Related Party Transactions	Note 8 – Related Party Transactions On June 19, 2014, we issued 45,000,000 shares of common stock, valued at $.003 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On June 19, 2014, we issued 45,000,000 shares of common stock, valued at $.003 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 26,562,500, shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 21,476,435shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 26,562,500 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 21,250,000 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 7,682,165 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. As of June 30, 2015, the Company has advanced approximately $50,900 to the officers of the company. Additionally, the officers of the Company waived their monthly salary accrual from July 1, 2014 to December 31, 2014. The Company has accrued officer salaries of $90,000 and $132,500 and paid $18,000 and 10,192 for the six months ended June 30, 2015 and 2014, respectively.

Litigation

Litigation	6 Months Ended
	Jun. 30, 2015
Litigation:
Litigation	Note 9 – Litigation The Company previously reported, on April 29, 2013 a former employee of the Company, Reid Jilek, sued the Company, its two directors and its three officers in San Diego County (California) Superior Court for breach of contract, retaliation, constructive discharge, failure to pay wages, failure to reimburse, conversion and fraudulent inducement. The complaint related to his employment agreement with the Company and his resignation which was effective in January 2013. The trial was held in September 2014. On September 26, 2014 the Court ruled in favor of the Company and against all of Jilek’s claims, and ruled that the Company was the prevailing party, and therefore was entitled to recover its attorney’s fees and costs from Jilek. The Company did not prevail in its cross-claims against Jilek. Jilek’s claims against the Company’s directors and officers had previously been dismissed.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2015
Subsequent Events:
Subsequent Events	Note 10 – Subsequent Events On July 15, 2015, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On August 31, 2015, we issued 10,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On September 25, 2015, we issued 5,000,000 shares of common stock, valued at $.0046 per share, for consulting services. On October 1, 2015, we issued 23,000,000 shares of common stock, valued at $.0063 per share, for consulting services. On October 14, 2015, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On October 16, 2015, we issued 4,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 9, 2015, we issued 3,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 17, 2015, we issued 7,500,000 shares of common stock, valued at $.0041 per share, for consulting services. On November 23, 2015, we issued 20,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 30, 2015, we issued 2,500,000 shares of common stock, valued at $.01 per share, for legal services. On January 4, 2016, we issued 2,500,000 shares of common stock, valued at $.004 per share, for consulting services. On January 22, 2016, we issued 2,500,000 shares of common stock, valued at $.0035 per share, for consulting services. On February 1, 2016, we issued 2,500,000 shares of common stock, valued at $.003 per share, for consulting services. On February 5, 2016, we issued 8,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On February 22, 2016, we issued 5,451,000 shares of common stock, valued at $.003 per share, in regard to a License Agreement (Form 8-K filed on February 25, 2016). Add detail payment schedule. Euro 250,000, Euro 275,000, Euro 300,000, Euro 375,000, and Euro 500,000 On February 26, 2016, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On March 7, 2016, we issued 10,000,000 shares of common stock, valued at $.004 per share, for consulting services. On March 21, 2016, we issued 100,800,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On May 2, 2016, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement and 1,000,000 shares of common stock, valued at $.0053 per share, for consulting services. On May 26, 2016, we issued 2,500,000 shares of common stock, valued at $.0066 per share, for consulting services. On May 26, 2016, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On May 31, 2016, we issued 2,500,000 shares of common stock, valued at $.0066 per share, for legal services. On July 8, 2015, the United States Patent and Trademark Office (the “USPTO”) accepted U.S. Application No. 62/190170 titled “Augmentation of Oncology Immunotherapies by Pterostilbene Containing Compositions”. On July 21, 2015, the United States Patent and Trademark Office (the “USPTO”) accepted U.S. Application No. 62/194990 titled “Prevention of Pregnancy Complications by Probiotic Administration”. On September 02, 2015, the United States Patent and Trademark Office (the “USPTO”) accepted U.S. Application No. 62/213260 titled “Preventative Methods and Therapeutic or Pharmaceutical Compositions for the Treatment or Prevention of Pregnancy Complications”. On September 15, 2015, the United States Patent and Trademark Office (the “USPTO”) accepted U.S. Application No. 62/219020 titled “Diagnostic Methods For The Assessment Of Pregnancy Complications”. On September 25, 2015, the United States Patent and Trademark Office (the “USPTO”) accepted U.S. Application No. 62/232722 titled “A Medical Device For Reducing The Risk Of Preterm-Labor And Preterm-Birth”. On October 20, 2015, OmniBiome, Inc, a partially-owned subsidiary of the Company, was incorporated in the State of Delaware. On October 28, 2015, MolecuVax, Inc., a partially-owned subsidiary of the Company, was incorporated in the State of Delaware. On November 18, 2015, Therapeutic Solutions International, Inc. licensed certain intellectual property to OmniBiome, Inc., a partially-owned subsidiary of Therapeutic Solutions International, Inc., as follows: (1) Application No. 62/213260 titled “Preventative Methods and Therapeutic or Pharmaceutical Compositions for the Treatment or Prevention of Pregnancy Complications” covers utility of vaccines and various agents to alter pathological conditions in which the maternal immune system induces a process of inflammation that culminates in placental alterations leading to either fetal loss or preterm labor; (2) Application No. 62/219020 “Diagnostic Methods For The Assessment Of Pregnancy Complications” a cytokine-based diagnostic kit aimed at stratifying risk of preterm labor and other pregnancy associated complications; and (3) Application No. 62/232722 “A Medical Device For Reducing The Risk Of Preterm-Labor And Preterm-Birth” covering various medical devices aimed at immune modulating the cervical microenvironment in order to prevent preterm labor. On November 20, 2015, the United States Patent and Trademark Office (the “USPTO”) accepted U.S. Application No. 62/258007 titled “Exosome Mediated Innate and Adaptive Immune Stimulation for Treatment of Cancer”. On December 04, 2015, Therapeutic Solutions International, Inc. licensed certain intellectual property to OmniBiome, Inc., a partially-owned subsidiary of Therapeutic Solutions International, Inc., Application No. 62/194990 titled “Prevention of Pregnancy Complications by Probiotic Administration.” On January 21, 2016, our Board of Directors elected Thomas E. Ichim, Ph.D, to fill a vacant seat on our Board of Directors. On February 05, 2016, Therapeutic Solutions International, Inc. licensed certain intellectual property to MolecuVax, Inc., a partially-owned subsidiary of Therapeutic Solutions International, Inc., Application No. 62/258,007 titled “Exosome Mediated Innate and Adaptive Immune Stimulation for Treatment of Cancer.” On April 27, 2016, the United States Patent and Trademark Office (the “USPTO”) accepted U.S. Application No. 62/327756 titled “Augmentation Of Stem Cell Activity Using Pterostilbene And Compositions Containing Pterostilbene”.

Accounting Policies (Policies)

Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies:
Estimates	Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash, Policy	Cash For the Statements of Cash Flows, all highly liquid investments with maturity of three months or less are considered to be cash equivalents. There were no cash equivalents as of June 30, 2015 and 2014. Other assets include restricted cash of $10,000 that is used to secure a company credit card.
Inventory, Policy	Inventory Inventory consists of finished goods, and is stated at the lower of cost or market. The Company records cost of sales using the moving average cost method. There was no excess or obsolete inventory reserve at June 30, 2015 and December 31, 2014.
Depreciation and Amortization, Policy	Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement.
Intangible Assets, Policy	Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutrasecutal formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.”
Long-lived Assets	Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. During the year ended December 31, 2014, the Company recognized an impairment charge of $210,000 for intangible assets.
Income Taxes, Policy	Income Taxes The Company accounts for income taxes under ASC 740 “Income Taxes,” “Accounting for Income Taxes” “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.”
Going Concern	Going Concern The Company’s financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has experienced recurring losses over the past years which have resulted in accumulated deficits of approximately $2,822 thousand and a working capital deficit of approximately $184 thousand at June 30, 2015. These conditions raise uncertainty about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is contingent upon its ability to secure additional financing, increase sales of its products and attain profitable operations. It is the intent of management to continue to raise additional capital. However, there can be no assurance that the Company will be able to secure such additional funds or obtain such on terms satisfactory to the Company, if at all. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
Share Based Expenses	Share Based Expenses ASC 718 “Compensation - Stock Compensation,” The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50 “Equity-Based Payments to Non-Employees,” “Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring or in Conjunction with Selling, Goods or Services”.
Recently Implemented Standards	Recently Implemented Standards The Company has implemented all new accounting pronouncements that are in effect that may impact its financial statements and does not believe that there are any new accounting pronouncements that have been issued that might have a material impact on its financial statements.

Schedule of Cost and accumulate

Schedule of Cost and accumulated depreciation of fixed assets and equipment (Tables)	6 Months Ended
	Jun. 30, 2015
Schedule of Cost and accumulated depreciation of fixed assets and equipment:
Schedule of Cost and accumulated depreciation of fixed assets and equipment	The cost and accumulated depreciation of fixed assets and equipment at June 30, 2015 and December 31, 2014 are summarized below: June 30, 2015 December 31, 2014 Computer Hardware $ 10,747 $ 10,747 Office Furniture and Equipment 3,639 3,639 Shipping and Other Equipment 1,575 1,575 Total 15,961 15,961 Accumulated Depreciation (15,961) (15,961) Property and Equipment, net $ - $ -

Schedule of Summary of Results

Schedule of Summary of Results of Discontinued Operations (Tables)	6 Months Ended
	Jun. 30, 2015
Schedule of Summary of Results of Discontinued Operations
Schedule of Summary of Results of Discontinued Operations	The following are the summarized results of discontinued operations for the three and six months ended June 30, 2015 and 2014 and the Balance Sheet as of June 30, 2015and December 31, 2014: For the Three Months ended June 30, 2015 For the Three Months ended June 30, 2014 For the Six Months ended June 30, 2015 For the Six Months ended June 30, 2014 Net international revenues $ - $ 68,879 $ - $ 144,298 Cost of goods sold - (1,663) - (3,583) Selling expenses - (1,997) - (4,578) Bad debt (4,670) - (4,670) - Obsolete inventory (4,052) - (4,052) - Other income from discontinued operations - - - 12,433 $ (8,772) $ 65,219 $ (8,772) $ 148,570 June 30, 2015 December 31, 2014 Assets Accounts Receivable, net - 46,845 Total assets of discontinued operations $ - $ 46,845

Cash (Details)

Cash (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Cash Details
Other assets include restricted cash	$ 10,000	$ 10,000

Going Concern (Details)

Going Concern (Details)	Jun. 30, 2015USD ($)
Going Concern Details
Accumulated deficit (approx)	$ 2,822,000
Working capital deficit (approx)	$ 184,000

Restricted Cash (Details)

Restricted Cash (Details)	Jun. 30, 2015USD ($)
Restricted Cash Details
Other non-current asset certificate of deposit	$ 10,000
Annual interest rate	0.60%

Equipment (Details)

Equipment (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Equipment Consists Of the Following:
Computer Hardware	$ 10,747	$ 10,747
Office Furniture and Equipment	3,639	3,639
Shipping and Other Equipment	1,575	1,575
Total Equipment	15,961	15,961
Accumulated Depreciation	(15,961)	(15,961)
Property and equipment, net	$ 0	$ 0

Equipment - Depreciation (Detai

Equipment - Depreciation (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Equipment - Depreciation Details
Depreciation expense	$ 0	$ 21,133

Intangible Asset (Details)

Intangible Asset (Details) - USD ($)	Dec. 31, 2014	Dec. 09, 2014
Intangible Asset Details
Issued shares for the rights, title and interest		100,000,000
Fair value of the shares of common stock recorded as intangible assets	$ 210,000
Impairment of intangible assets	$ 210,000

Capital Stock Transactions (Det

Capital Stock Transactions (Details)	Jun. 30, 2015$ / sharesshares
PREFERRED STOCK:
Preferred Stock, shares authorized | shares	5,000,000
Preferred Stock, par value | $ / shares	$ 0.001
COMMON STOCK:
Common Stock shares authorized | shares	699,999,999
Common Stock, par value | $ / shares	$ 0.001
Voting rights	50.00%

Capital Stock Transactions Duri

Capital Stock Transactions During 2014 (Details) - $ / shares	Dec. 09, 2014	Sep. 30, 2014	Jun. 19, 2014	Mar. 31, 2014
Capital Stock Transactions During 2014 (Details)
Issued shares of common stock for consulting services				2,500,000
Issued shares of common stockfor consulting services per share				$ 0.0035
Issued shares of common stock for consulting services				2,500,000
Issued shares of common stockfor consulting services per share				$ 0.004
Issued shares of common stock for consulting services				2,000,000
Issued shares of common stockfor consulting services per share				$ 0.0035
Issued shares of common stock for legal services				5,000,000
Issued shares of common stock for legal services per share				$ 0.006
Issued shares of common stock for a conversion of notes payable for accrued wages		26,562,500	45,000,000
Issued shares of common stock for a conversion of notes payable for accrued wages per share		$ 0.002	$ 0.003
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages		21,476,435	45,000,000
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share		$ 0.002	$ 0.003
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages		26,562,500
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share		$ 0.002
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages		21,250,000
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share		$ 0.002
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages		7,682,165
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share		$ 0.002
Issued shares of common stockin regard to a Material Definitive Agreement	100,000,000
Issued shares of common stockin regard to a Material Definitive Agreement per share	$ 0.0021

Capital Stock Transactions Du28

Capital Stock Transactions During 2015 (Details) - $ / shares	Nov. 30, 2015	Nov. 23, 2015	Nov. 17, 2015	Nov. 09, 2015	Oct. 16, 2015	Oct. 14, 2015	Oct. 01, 2015	Sep. 25, 2015	Aug. 31, 2015	Jul. 15, 2015	Jun. 08, 2015	Jun. 01, 2015	Apr. 17, 2015	Apr. 01, 2015	Mar. 27, 2015
Capital Stock Transactions During 2015
Shares of common stock for consulting services			7,500,000				23,000,000	5,000,000				3,000,000		10,000,000	2,000,000
Shares of common stock for consulting services per share			$ 0.0041				$ 0.0063	$ 0.0046				$ 0.0026		$ 0.0025	$ 0.0025
Shares of common stock for Private Placement		20,000,000		3,000,000	4,000,000	2,000,000			10,000,000	10,000,000	1,000,000		20,000,000		20,000,000
Shares of common stock for Private Placement per share		$ 0.0025		$ 0.0025	$ 0.0025	$ 0.0025			$ 0.0025	$ 0.0025	$ 0.0025		$ 0.0025		$ 0.0025
Shares of common stock for legal services	2,500,000											7,000,000
Shares of common stock for legal services per share	$ 0.01											$ 0.0025

Capital Stock Transactions Du29

Capital Stock Transactions During 2016 (Details) - $ / shares	May 31, 2016	May 26, 2016	May 02, 2016	Mar. 21, 2016	Mar. 07, 2016	Feb. 26, 2016	Feb. 22, 2016	Feb. 05, 2016	Feb. 01, 2016	Jan. 22, 2016	Jan. 04, 2016
Capital Stock Transactions During 2016
Issued shares of common stock for consulting services		2,500,000	1,000,000		10,000,000				2,500,000	2,500,000	2,500,000
Issued shares of common stockfor consulting services per share		$ 0.0066	$ 0.0053		$ 0.004				$ 0.003	$ 0.0035	$ 0.004
Issued shares of common stock for for an investment in Private Placement		2,000,000	1,000,000	100,800,000		1,000,000		8,000,000
Issued shares of common stock for an investment in Private Placement per share		$ 0.0025	$ 0.0025	$ 0.0025		$ 0.0025		$ 0.0025
Issued shares of common stock in regard to a License Agreement							5,451,000
Issued shares of common stock in regard to a License Agreement per share							$ 0.003
Issued shares of common stock for legal services	2,500,000
Issued shares of common stock for legal services per share	$ 0.0066

Results of discontinued operati

Results of discontinued operations (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Results of discontinued operations details
Net international revenues	$ 0	$ 68,879	$ 0	$ 144,298
Cost of goods sold	0	(1,663)	0	(3,583)
Selling expenses	0	(1,997)	0	(4,578)
Bad debt	(4,670)	0	(4,670)	0
Obsolete inventory	(4,052)	0	(4,052)	0
Other income from discontinued operations	0	0		12,433
Total discontinued operations	(8,772)	$ 65,219	(8,772)	$ 148,570
Assets discontinued operations
Accounts Receivable, net	0		0		$ 46,845
Total assets of discontinued operations	$ 0		$ 0		$ 46,845

Related Party Transactions Agre

Related Party Transactions Agreement (Details) - USD ($)	Jun. 30, 2015	Sep. 30, 2014	Jun. 30, 2014	Jun. 19, 2014
Related Party Transactions Agreement:
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages		26,562,500		45,000,000
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share		$ 0.002		$ 0.003
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages		21,476,435		45,000,000
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share		$ 0.002		$ 0.003
Shares of common stock to an officer for a conversion of notes payable for accrued wages		26,562,500
Shares of common stock to an officer for a conversion of notes payable for accrued wages valued at per share		$ 0.002
Shares of common stock to an officer for a conversion of notes payable for accrued wages		21,250,000
Shares of common stock to an officer for a conversion of notes payable for accrued wages valued at per share		$ 0.002
Shares of common stock to an officer for a conversion of notes payable for accrued wages		7,682,165
Shares of common stock to an officer for a conversion of notes payable for accrued wages valued at per share		$ 0.002
Advanced to the officers	$ 50,900
Accrued officers salary	90,000		$ 132,500
Paid officers salary	$ 18,000		$ 10,192

Subsequent Events During 2015 (

Subsequent Events During 2015 (Details) - $ / shares	Nov. 30, 2015	Nov. 23, 2015	Nov. 17, 2015	Nov. 09, 2015	Oct. 16, 2015	Oct. 14, 2015	Oct. 01, 2015	Sep. 25, 2015	Aug. 31, 2015	Jul. 15, 2015
Subsequent Events During 2015 Details
Shares of common stock for consulting services			7,500,000				23,000,000	5,000,000
Shares of common stock for consulting services per share			$ 0.0041				$ 0.0063	$ 0.0046
Shares of common stock for Private Placement		20,000,000		3,000,000	4,000,000	2,000,000			10,000,000	10,000,000
Shares of common stock for Private Placement per share		$ 0.0025		$ 0.0025	$ 0.0025	$ 0.0025			$ 0.0025	$ 0.0025
Shares of common stock for legal services	2,500,000
Shares of common stock for legal services per share	$ 0.01

Subsequent Events During 2016 (

Subsequent Events During 2016 (Details) - $ / shares	May 31, 2016	May 26, 2016	May 02, 2016	Mar. 21, 2016	Mar. 07, 2016	Feb. 26, 2016	Feb. 22, 2016	Feb. 05, 2016	Feb. 01, 2016	Jan. 22, 2016	Jan. 04, 2016
Subsequent Events During 2016
Issued shares of common stock for consulting services		2,500,000	1,000,000	100,000,000	10,000,000				2,500,000	2,500,000	2,500,000
Issued shares of common stockfor consulting services per share		$ 0.0066	$ 0.0053	$ 0.0025	$ 0.0025				$ 0.003	$ 0.0035	$ 0.004
Issued shares of common stock for for an investment in Private Placement		2,000,000	1,000,000			1,000,000		8,000,000
Issued shares of common stock for an investment in Private Placement per share		$ 0.0025	$ 0.0025			$ 0.0025		$ 0.0025
Issued shares of common stock in regard to a License Agreement							5,451,000
Issued shares of common stock in regard to a License Agreement per share							$ 0.003
Common shares of holdings in MolecuVax, Inc. retired to treasury			62,500,000
Common shares currently owned in MolecuVax, Inc.			37,500,000
Issued shares of common stock for legal services	2,500,000
Issued shares of common stockfor legal services per share	$ 0.0066